Atossa Therapeutics, Inc. (ATOS)
NASDAQ: ATOS · Real-Time Price · USD
2.170
-0.060 (-2.69%)
At close: Oct 30, 2026, 4:00 PM EDT
2.279
+0.109 (5.04%)
After-hours: Oct 30, 2026, 7:30 PM EDT
Atossa Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
16
Market Cap
21.66M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Karyopharm Therapeutics | 146.62M |
| BioStem Technologies | 34.59M |
| Immutep | 13.79M |
| Evaxion | 7.49M |
| Seres Therapeutics | 1.88M |
| BeyondSpring | 1.88M |
| IGC Pharma | 1.11M |
| Cocrystal Pharma | 330.00K |
ATOS News
- 12 days ago - Atossa Therapeutics says common stock to begin trading with stapled CVR - TheFly
- 12 days ago - Atossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business Today - PRNewsWire
- 22 days ago - Atossa Therapeutics enters Stapled Contingent Value Rights Agreement - TheFly
- 22 days ago - Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value - PRNewsWire
- 4 weeks ago - Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher - PRNewsWire
- 5 weeks ago - Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging - PRNewsWire
- 6 weeks ago - Atossa Therapeutics Slides: Corporate presentation - Filings
- 2 months ago - Atossa Therapeutics reports Q2 EPS (95c) vs. (98c) last year - TheFly